Cargando…

Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent

PURPOSE: The aim of this study was to examine the rate and timing of hemoglobin decline from <10 g/dL to <9 g/dL in cancer patients receiving chemotherapy. METHODS: Pooled data from the placebo arms of six randomized, controlled trials (RCTs) of darbepoetin alfa and data from an aggregated US...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pirker, Robert, Pirolli, Melissa, Quigley, Jane, Hulnick, Scott, Legg, Jason, Collins, Helen, Vansteenkiste, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584249/ https://www.ncbi.nlm.nih.gov/pubmed/23096072 http://dx.doi.org/10.1007/s00520-012-1617-2

Ejemplares similares

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

Use of Erythropoiesis-Stimulating Agents Among Chemotherapy Patients With Hemoglobin Exceeding 12 Grams Per Deciliter
por: Nordstrom, Beth L., et al.
Publicado: (2008)

Mechanisms of hemoglobin cycling in anemia patients treated with erythropoiesis-stimulating agents
por: Jörg, David J., et al.
Publicado: (2023)

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients
por: Nguyen, Timothy V., et al.
Publicado: (2011)

The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
por: Sibbel, Scott, et al.
Publicado: (2016)

Neuroimaging in Former Preterm Children Who Received Erythropoiesis Stimulating Agents
por: Phillips, Authors: John, et al.
Publicado: (2017)

Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
por: Pashos, Chris L., et al.
Publicado: (2011)

Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study
por: Castillo, Nieves, et al.
Publicado: (2012)

Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease
por: El Hoss, Sara, et al.
Publicado: (2020)

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
por: Glaspy, J, et al.
Publicado: (2010)

Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome
por: Bernieh, Bassam, et al.
Publicado: (2014)

Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada
por: Canney, Mark, et al.
Publicado: (2021)

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients
por: Gupta, Ajay, et al.
Publicado: (2015)

Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis
por: Khan, Irfan, et al.
Publicado: (2011)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

THE RELATIONSHIP BETWEEN RNA SYNTHESIS AND HEMOGLOBIN SYNTHESIS IN AMPHIBIAN ERYTHROPOIESIS : Cytochemical Evidence
por: Grasso, Joseph A., et al.
Publicado: (1966)

THE EFFECT OF HEMOGLOBIN INJECTIONS ON ERYTHROPOIESIS AND ERYTHROCYTE SIZE IN RABBITS RENDERED ANEMIC BY BLEEDING
por: Miller, D. K., et al.
Publicado: (1934)

Budget impact analysis on erythropoiesis–stimulating agents use for the management of chemotherapy-induced anaemia in Greece
por: Nikolaidi, Eleftheria, et al.
Publicado: (2013)

Staff Time and Motion Assessment for Administration of Erythropoiesis-Stimulating Agents: A Two-Phase Pilot Study in Clinical Oncology Practices
por: Reitan, John F., et al.
Publicado: (2013)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

Prediction of hemoglobin levels in individual hemodialysis patients by means of a mathematical model of erythropoiesis
por: Fuertinger, Doris H., et al.
Publicado: (2018)

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience
por: Rodriguez Garzotto, Analia, et al.
Publicado: (2014)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States
por: Arellano, Jorge, et al.
Publicado: (2015)

PRIMITIVE ERYTHROPOIESIS IN EARLY CHICK EMBRYOGENESIS : II. Correlation between Hemoglobin Synthesis and the Mitotic History
por: Campbell, G. Le M., et al.
Publicado: (1971)

ERYTHROPOIESIS DURING AMPHIBIAN METAMORPHOSIS : II. Immunochemical Study of Larval and Adult Hemoglobins of Rana catesbeiana
por: Maniatis, George M., et al.
Publicado: (1971)

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience [Corrigendum]
Publicado: (2014)

End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia
por: Hoque, Shamia, et al.
Publicado: (2020)

The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients
por: Kwon, Owen, et al.
Publicado: (2015)

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy
por: Glaspy, J, et al.
Publicado: (2001)

Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
por: Cizman, Borut, et al.
Publicado: (2020)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents
por: Yan, X, et al.
Publicado: (2013)

Erythropoiesis stimulating agents and reno-protection: a meta-analysis
por: Elliott, Steve, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hgpe1hao2ej1vb5plt0ak6bm9d